The Broad Institute, Inc.

Massachusetts Institute of Technology

The General Hospital Corporation

University of Kansas

Patrick Faloon

Benito Munoz

Monty Krieger

Sivaraman Dandapani

Partha Pratim Nag

Miao Yu

Willmen Youngsaye

Chris Dockendorff

Thomas Nieland

Timothy A Lewis

Frank John Schoenen

David E Fisher

Warren S Weiner

Andrew Germain

Rizwan Haq

Robert Smith

This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.

Thiazole-based inhibitors of scavenger receptor BI

This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein Rand Rare independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or Rand Rtogether are &#x2014;O&#x2014;CH&#x2014; or &#x2014;O&#x2014;CF&#x2014;O&#x2014;; Ris H, halogen, cyano, haloalkyl or haloalkyloxy; Ris Calkyl, Ccycloalkyl, Ccycloalkylmethyl or Ccycloheteroalkyl, wherein the heteroatom is N or O; Ris H or CH; Ris Calkyl or Ccycloalkyl; and A, B, D and E are each, independently, CH, N, O or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, O or S. 

Heterocycle-bisamide inhibitors of scavenger receptor BI

Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer. 

Inhibitors of the MITF molecular pathway

Growing community of inventors

Cambridge, MA, United States of America

Patrick Faloon